Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Commentary

  • 1,919 Articles
  • 0 Posts
  • ← Previous
  • 1
  • 2
  • 3
  • …
  • 191
  • 192
  • Next →
NR2F1 and mTORC1 provide the bridge between melanoma dormancy and therapeutic resistance
Narsimha Mamidi, … , Swadesh K. Das, Paul B. Fisher
Narsimha Mamidi, … , Swadesh K. Das, Paul B. Fisher
Published September 16, 2025
Citation Information: J Clin Invest. 2025;135(18):e197764. https://doi.org/10.1172/JCI197764.
View: Text | PDF

NR2F1 and mTORC1 provide the bridge between melanoma dormancy and therapeutic resistance

  • Text
  • PDF
Abstract

Cutaneous melanoma (CM) is known for its aggressive behavior, high metastatic potential, and poor prognosis. Mutations in the BRAF gene are common in CM, and patients with BRAF-mutant melanoma often respond well to combined inhibition of BRAF and MEK (BRAFi + MEKi). Although BRAFi + MEKi therapy provides clinical efficacy, the response durability is limited by persistent drug-tolerant residual cells, culminating in relapse. In this issue of the JCI, Tiago et al. confirmed that NR2F1, a dormancy-associated transcription factor, is a key determinant of therapeutic resistance in melanoma. NR2F1 expression was elevated in transcriptomic datasets from patients with minimal residual disease, and in murine and human melanoma models, NR2F1 overexpression reduced therapeutic efficacy and suppressed tumor proliferation and invasion while sustaining mechanistic target of rapamycin complex 1 (mTORC1) transcriptional regulation of relevant genes. Combining BRAFi + MEKi with the mTORC1 inhibitor rapamycin effectively targeted these resistant melanoma cells, suggesting a potential path forward for targeting NR2F1 and mTORC1 signaling in patients with CM.

Authors

Narsimha Mamidi, Swadesh K. Das, Paul B. Fisher

×

Unraveling endocannabinoid signaling disruption in a preclinical model of neurodevelopmental disorders
Nephi Stella
Nephi Stella
Published September 2, 2025
Citation Information: J Clin Invest. 2025;135(17):e196707. https://doi.org/10.1172/JCI196707.
View: Text | PDF

Unraveling endocannabinoid signaling disruption in a preclinical model of neurodevelopmental disorders

  • Text
  • PDF
Abstract

The search for transformative medicines has continuously uncovered select diseases associated with the disruption of the endocannabinoid (eCB) signaling system in the brain and emphasized the therapeutic value of small molecules that rescue this signaling system. In this issue of JCI, Wang et al. report that genetic disruption of PPP2R1A function in mouse forebrain, a preclinical mouse model of neurodevelopmental disorders, resulted in pronounced impairment of eCB signaling. Notably, small-molecule inhibitors of eCB inactivation rescued both eCB signaling and cognitive dysfunction in this model, providing a solid foundation to move such transformative therapeutic approaches based on targeting eCB signaling toward human clinical trial testing.

Authors

Nephi Stella

×

Cerebrospinal fluid flow modulates brain health
Lauren M. Hablitz, Maiken Nedergaard
Lauren M. Hablitz, Maiken Nedergaard
Published September 2, 2025
Citation Information: J Clin Invest. 2025;135(17):e197202. https://doi.org/10.1172/JCI197202.
View: Text | PDF

Cerebrospinal fluid flow modulates brain health

  • Text
  • PDF
Abstract

Cerebrospinal fluid dynamics play an important role in maintaining brain health and clearing metabolic waste from the brain. In this issue of the JCI, Gursky et al. investigate how CSF distribution is affected when its primary efflux pathway — the deep cervical lymph nodes — is disrupted by cauterization. This timely study reveals compensatory fluid drainage routes from the skull, age-dependent adaptations in CSF homeostasis, and the emergence of neuroinflammation when an efflux pathway is occluded. The findings underscore the need to better understand the physiological mechanisms governing CSF clearance, how these pathways evolve with aging, and whether CSF influx and efflux exhibit region-specific dynamics shaped by neuroanatomy. Additionally, the study raises important questions about whether peripheral injury can influence central nervous system states. A more complete understanding of CSF flow regulation may offer new perspectives on the origins of neuropathology.

Authors

Lauren M. Hablitz, Maiken Nedergaard

×

Targeting LAIR1-mediated immunosuppression adds a new weapon to our immunotherapy arsenal
Ezri P. Perrin, … , Hannah K. Dorando, Jacqueline E. Payton
Ezri P. Perrin, … , Hannah K. Dorando, Jacqueline E. Payton
Published August 15, 2025
Citation Information: J Clin Invest. 2025;135(16):e194924. https://doi.org/10.1172/JCI194924.
View: Text | PDF

Targeting LAIR1-mediated immunosuppression adds a new weapon to our immunotherapy arsenal

  • Text
  • PDF
Abstract

Leukocyte-associated Ig-like receptor 1 (LAIR1) is a collagen-binding inhibitory immune receptor that negatively regulates cellular activation. In this issue of the JCI, Tao et al. show that LAIR1-inhibitory signaling plays an important role in immunosuppressive M2-like tumor-associated macrophages (TAMs) in aggressive brain tumors. LAIR1 KO, antibody blockade, and an immunotherapy that incorporates a LAIR1-inhibitory module into a chimeric antigen receptor (CAR) all led to increased antitumor activity by CAR T cells, reduced M2-like TAMs, altered collagen networks, and increased survival rates in mouse tumor models. These findings demonstrate an innovative immunotherapeutic approach for cancer that leverages LAIR1 inhibition to combat multiple tumor immune evasion strategies.

Authors

Ezri P. Perrin, Hannah K. Dorando, Jacqueline E. Payton

×

Chronic diseases alter the platelet rheostat to promote hyperreactivity and thrombosis
Roy L. Silverstein
Roy L. Silverstein
Published August 15, 2025
Citation Information: J Clin Invest. 2025;135(16):e194082. https://doi.org/10.1172/JCI194082.
View: Text | PDF

Chronic diseases alter the platelet rheostat to promote hyperreactivity and thrombosis

  • Text
  • PDF
Abstract

Platelet hyperreactivity, defined as enhanced sensitivity to activation in response to classical agonists, contributes to the increased risk of arterial thrombosis associated with chronic inflammatory diseases. In this issue of the JCI, Kong and colleagues used an unbiased proteomic approach to identify elevated SEC61B in platelets from patients with diabetes and from hyperglycemic mice. Typically, SEC61B participates in protein transport within the endoplasmic reticulum (ER), but it can also act as an ion channel that allows calcium to leak from ER to cytoplasm. The authors showed that elevated SEC61B expression caused increased calcium leak, elevated basal cytoplasmic calcium concentrations, and platelet hyperreactivity. In vitro and in vivo pharmacological interventions to alter calcium homeostasis through this pathway affected platelet reactivity. The results of this work are consistent with those of previous studies showing that platelets from patients with chronic diseases behaved differently than those from healthy participants. These findings identify potential disease-specific targets to prevent and treat arterial thrombosis.

Authors

Roy L. Silverstein

×

Genetic risk in telomere biology disorders: it adds up
Tanner O. Monroe
Tanner O. Monroe
Published August 15, 2025
Citation Information: J Clin Invest. 2025;135(16):e195921. https://doi.org/10.1172/JCI195921.
View: Text | PDF

Genetic risk in telomere biology disorders: it adds up

  • Text
  • PDF
Abstract

For many conditions, genotyping aids in clinical decision making. However, interpreting the clinical significance of genetic variants remains challenging, in part because a single risk variant does not always lead to disease, and variant carriers experience variable outcomes. One hypothesis underlying these phenomena, which are known as incomplete penetrance and variable expressivity, respectively, is that additional common genetic variation beyond the primary variant influences the presence and severity of disease. In this issue of JCI, Poeschla et al. present a compelling argument that common variants linked to telomere length act together with high-risk telomere biology disorder variants to scale outcomes. These data support a model in which many variants interact to shape cumulative risk.

Authors

Tanner O. Monroe

×

EV-D68 neurological disease: tipping the scales toward immunopathogenesis
Peter W. Krug
Peter W. Krug
Published August 1, 2025
Citation Information: J Clin Invest. 2025;135(15):e195839. https://doi.org/10.1172/JCI195839.
View: Text | PDF

EV-D68 neurological disease: tipping the scales toward immunopathogenesis

  • Text
  • PDF
Abstract

Over the last decade, there have been multiple outbreaks of enterovirus D68 (EV-D68) disease and associated cases of acute flaccid myelitis (AFM). The underlying cause of EV-D68–induced AFM is contentious; whether spinal cord motor neurons are damaged by direct viral infection, infiltration of immune cells, or a combination of both is not clear. In this issue of the JCI, Woods Acevedo and coworkers used a neonatal WT mouse model of EV-D68 infection to attribute paralytic disease to immune cell infiltration into the spinal cord. The results of their work in cytokine-knockout or immune cell–depleted animals effectively argue that immunopathogenesis plays an integral role in EV-D68–induced AFM.

Authors

Peter W. Krug

×

Uncovering phenotypic heterogeneity through research autopsy in lethal prostate cancer
Sylvie S.W. Chan, … , Osvaldas Vainauskas, Gerhardt Attard
Sylvie S.W. Chan, … , Osvaldas Vainauskas, Gerhardt Attard
Published August 1, 2025
Citation Information: J Clin Invest. 2025;135(15):e195102. https://doi.org/10.1172/JCI195102.
View: Text | PDF

Uncovering phenotypic heterogeneity through research autopsy in lethal prostate cancer

  • Text
  • PDF
Abstract

Tumor heterogeneity in metastatic prostate cancer (mPC) is well established, but comprehensive characterization using routine sampling remains challenging. Autopsy-based research addresses this obstacle by enabling broad tissue collection within individual patients after treatment. In this issue of the JCI, Roudier et al. analyzed samples from a mPC research autopsy cohort, revealing extensive inter- and intratumor heterogeneity across patients and at the cellular level. The authors associated this variability with genomic, phenotypic, and clinical features and explored the importance of tumors expressing both androgen receptor and neuroendocrine markers. Their findings demonstrate heterogeneity across metastatic sites that may influence treatment response and clinical outcomes, informing future therapeutic strategies in mPC.

Authors

Sylvie S.W. Chan, Osvaldas Vainauskas, Gerhardt Attard

×

KS-WNK1 augments the effects of dietary potassium intake on renal sodium chloride reabsorption
Gerardo Gamba, David H. Ellison
Gerardo Gamba, David H. Ellison
Published August 1, 2025
Citation Information: J Clin Invest. 2025;135(15):e195512. https://doi.org/10.1172/JCI195512.
View: Text | PDF

KS-WNK1 augments the effects of dietary potassium intake on renal sodium chloride reabsorption

  • Text
  • PDF
Abstract

Clinically, potassium supplementation has been shown to lower blood pressure and reduce the risk of stroke through modulation of potassium excretion and sodium reabsorption. Hypokalemia activates the renal sodium chloride cotransporter (NCC) along the distal convoluted tubule (DCT), at least in part, through with-no-lysine 4 (WNK4) kinase and STE20/SPS1-related proline-alanine-rich protein kinase (SPAK) signaling. The DCT also expresses a kinase-deficient, kidney-specific form of WNK1 (KS-WNK1), but its role in NCC activation is unclear. In this issue of the JCI, Boyd-Shiwarski and colleagues found that KS-WNK1 enhanced the effects of potassium on NCC activation in vivo. Specifically, they showed that mice lacking KS-WNK1 did not respond as robustly to dietary challenge. Additionally, in vivo expression of a mutated KS-WNK1 disrupted WNK body, or biomolecular condensate, formation and renal function. These findings, along with those of previous studies, indicate that KS-WNK1 may regulate potassium homeostasis by increasing the kidney’s sensitivity to salt-dependent stress.

Authors

Gerardo Gamba, David H. Ellison

×

Integrin α4β7 as a predictor of HIV acquisition: one thread in a complex tapestry
Tosin E. Omole, Lyle R. McKinnon
Tosin E. Omole, Lyle R. McKinnon
Published August 1, 2025
Citation Information: J Clin Invest. 2025;135(15):e195258. https://doi.org/10.1172/JCI195258.
View: Text | PDF

Integrin α4β7 as a predictor of HIV acquisition: one thread in a complex tapestry

  • Text
  • PDF
Abstract

Cellular susceptibility to HIV is associated with integrin α4β7, a mucosal homing receptor involved with trafficking HIV target cells to sites of HIV replication. However, studies investigating preinfection α4β7 expression as a predictor of HIV outcomes have yielded inconsistent findings, raising questions about the role of α4β7 in HIV acquisition across populations. In this issue of the JCI, Machmach et al. assessed PBMCs collected before HIV infection and found higher α4β7 expression on memory CD4+ T cells and invariant NK T (iNKT) cells in individuals who went on to acquire HIV. Here, we consider possible explanations that may underlie discrepancies among studies and suggest that α4β7 should be considered as part of a multifactorial profile for determining HIV risk. While unlikely to serve as a target for HIV prevention or therapy, α4β7-directed interventions may offer adjunctive benefits in preserving or improving mucosal immunity.

Authors

Tosin E. Omole, Lyle R. McKinnon

×
  • ← Previous
  • 1
  • 2
  • 3
  • …
  • 191
  • 192
  • Next →

No posts were found with this tag.

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts